CMRX - Chimerix, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.7700
+0.0400 (+2.31%)
At close: 4:00PM EST

1.7700 0.00 (0.00%)
After hours: 4:00PM EST

Stock chart is not supported by your current browser
Previous Close1.7300
Open1.7500
Bid1.7300 x 1300
Ask1.8000 x 2200
Day's Range1.7200 - 1.8100
52 Week Range1.2500 - 4.4000
Volume538,592
Avg. Volume508,027
Market Cap109.281M
Beta (5Y Monthly)1.58
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • GlobeNewswire

    Chimerix to Present at Cowen and Company 40th Annual Health Care Conference

    Chimerix (CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman, Chief Executive Officer, will present a corporate overview at the Cowen and Company 40th Annual Health Care Conference on Wednesday, March 4, 2020 at 8:40 a.m. ET in Boston, MA. A live audio webcast of the presentation will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days.

  • GlobeNewswire

    Chimerix Reports Fourth Quarter and Year End 2019 Financial Results and Provides Operational Update

    - Successful DSTAT End of Phase 2 Meeting with FDA Confirms Phase 3 Readiness; First Patient Visit Expected mid-2020 in 1L AML - - Brincidofovir pre-NDA Meeting Scheduled.

  • ACCESSWIRE

    Chimerix, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 25, 2020 / Chimerix, Inc. (NASDAQ:CMRX) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on February 25, 2020 at 8:30 ...

  • GlobeNewswire

    Chimerix Appoints Pratik S. Multani, M.D., to Board of Directors

    Chimerix (CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced the appointment of Pratik S. Multani, M.D., to its Board of Directors, effective immediately.

  • GlobeNewswire

    Chimerix to Report Fourth Quarter and Year End 2019 Financial Results and Provide an Operational Update on February 25, 2020

    Chimerix (CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that it will host a live conference call and audio webcast on Tuesday, February 25, 2020 at 8:30 a.m. ET to report financial results for the fourth quarter and full-year ended December 31, 2019, and to provide a business overview. An archived webcast will be available on the Chimerix website approximately two hours after the event. Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases.

  • GlobeNewswire

    Chimerix Presents Data Supporting Brincidofovir as a Potential Treatment for Smallpox at 2020 American Society for Microbiology Biothreats Meeting

    Chimerix (CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announces that data in support of brincidofovir (BCV) as a potential treatment for smallpox were highlighted in an oral presentation and poster at the 2020 American Society for Microbiology (ASM) Biothreats Meeting taking place January 28-30, 2020 in Arlington, Virginia. Chimerix is developing BCV as a medical countermeasure against smallpox.

  • GlobeNewswire

    Chimerix Presents Updated Results from Phase 2 Clinical Trial of DSTAT in Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia at American Society of Hematology Annual Meeting

    Chimerix, Inc. (CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that data relating to its dociparstat sodium (DSTAT) program, formerly known as CX-01, were presented at the 61st American Society of Hematology Annual Meeting, in Orlando, FL. The poster, titled “Updated Study Results for CX-01, an Inhibitor of CXCL12/CXCR4, With Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDS,” was presented by Eric Huselton, M.D., Assistant Professor of Medicine at the University of Rochester on December 9, 2019. As reported in the published study abstract, 20 patients with refractory myelodysplastic syndrome (MDS) (n = 9) or refractory acute myeloid leukemia (AML) (n = 11) were enrolled of which 15 were considered evaluable for response with a bone marrow biopsy after cycle 2.

  • GlobeNewswire

    Chimerix Announces Third Quarter 2019 Financial Results and Provides Operational Update

    – Final Data from Phase 2 Randomized Trial of DSTAT in First-line AML Support Enhanced Durability of Response, Event-free Survival and Overall Survival Benefit – – End of Phase.

  • GlobeNewswire

    Chimerix to Present at Upcoming Investor Conferences

    DURHAM, N.C., Nov. 04, 2019 -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious.

  • GlobeNewswire

    Chimerix to Announce Third Quarter 2019 Financial Results and Provide an Operational Update on November 5, 2019

    Chimerix, Inc. (CMRX), a biopharmaceutical company focused on accelerating the development of innovative medicines to treat patients with cancer and other serious diseases, today announced that it will host a live conference call and audio webcast on Tuesday, November 5, 2019 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2019, and to provide an operational update. A live audio webcast of the call will also be available on the Investors’ section of the Company's website, www.chimerix.com. Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases.

  • GlobeNewswire

    Chimerix Announces Exclusive Global License Agreement with SymBio Pharmaceuticals for Brincidofovir

    Chimerix (CMRX), a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases, today announces an exclusive global license agreement with SymBio Pharmaceuticals, Ltd (SymBio), under which SymBio has exclusively licensed the worldwide rights to develop, manufacture and commercialize brincidofovir in all human indications, excluding the prevention and treatment of smallpox. Moving forward, SymBio will be responsible for all future development and commercialization as well as manufacturing costs associated with brincidofovir in the licensed indications.

  • GlobeNewswire

    Chimerix to Present at 2019 Cantor Global Healthcare Conference

    DURHAM, N.C., Sept. 27, 2019 -- Chimerix (NASDAQ:CMRX) today announced that Mike Sherman, Chief Executive Officer, will present a corporate overview at the upcoming 2019 Cantor.

  • GlobeNewswire

    Chimerix Announces Second Quarter 2019 Financial Results and Operational Update

    Pipeline Transformed with Acquisition of Global Rights to Late Stage Oncology Asset (CX-01) with Fast Track and Orphan Drug Designation Phase 3 Trial of CX-01 in Front-Line.

  • GlobeNewswire

    Chimerix Announces Exclusive Worldwide License of Phase 3 Ready CX-01 for Development in Acute Myeloid Leukemia

    Chimerix (CMRX), today announced the completion of an exclusive worldwide license of CX-01 from Cantex Pharmaceuticals, Inc. Chimerix intends to move quickly into Phase 3 development of CX-01 for the treatment of Acute Myeloid Leukemia (AML) in the first-line setting. “We are pleased to have made such rapid progress in repositioning the company and transforming our pipeline with this important cancer therapy.

  • GlobeNewswire

    Chimerix Announces First Quarter 2019 Financial Results and Strategy Update

    – Reports Positive Top-line Survival Data from Pivotal Mouse Study as Key Milestone on Path to Smallpox Regulatory Submission – – Plan to Focus on Execution of Smallpox.

  • GlobeNewswire

    Chimerix to Announce First Quarter 2019 Financial Results on May 9, 2019

    DURHAM, N.C., May 02, 2019 -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, today.

  • GlobeNewswire

    Chimerix Announces Management Updates

    Chimerix (CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announces the appointment of Michael A. Sherman, former Chief Executive Officer of Endocyte, Inc., as Chief Executive Officer of Chimerix, effective immediately.

  • GlobeNewswire

    Chimerix Announces Fourth Quarter and Full Year 2018 Financial Results

    – Reports Positive Preliminary Top-line Data from Second Rabbitpox Study – – Type C Meeting Requested with FDA Regarding Virologic Endpoint – – Conference Call at 8:30.

  • GlobeNewswire

    Chimerix to Present at Cowen and Company 39th Annual Health Care Conference

    DURHAM, N.C., March 04, 2019 -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, today announced.